Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp trimmed its position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 9.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 540,072 shares of the company's stock after selling 54,551 shares during the period. Bank of New York Mellon Corp owned approximately 0.63% of Progyny worth $9,316,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Pacer Advisors Inc. raised its stake in shares of Progyny by 47.5% in the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock valued at $63,414,000 after acquiring an additional 1,183,558 shares in the last quarter. State Street Corp raised its stake in shares of Progyny by 4.5% in the third quarter. State Street Corp now owns 3,113,654 shares of the company's stock valued at $52,185,000 after acquiring an additional 134,861 shares in the last quarter. Invenomic Capital Management LP acquired a new stake in shares of Progyny in the third quarter valued at $29,509,000. Fort Washington Investment Advisors Inc. OH raised its stake in Progyny by 90.1% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock valued at $25,319,000 after buying an additional 695,740 shares in the last quarter. Finally, Baillie Gifford & Co. raised its stake in Progyny by 52.2% in the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company's stock valued at $22,989,000 after buying an additional 456,853 shares in the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PGNY. Bank of America raised their price target on Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Canaccord Genuity Group raised their price target on Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. raised their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Progyny presently has a consensus rating of "Hold" and a consensus price target of $24.82.

Remove Ads

Insider Activity

In related news, Chairman David J. Schlanger bought 150,000 shares of Progyny stock in a transaction dated Thursday, December 26th. The stock was acquired at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the acquisition, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This trade represents a 191.65 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Peter Anevski purchased 209,500 shares of the company's stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average cost of $14.48 per share, for a total transaction of $3,033,560.00. Following the completion of the transaction, the chief executive officer now directly owns 441,463 shares of the company's stock, valued at $6,392,384.24. This trade represents a 90.32 % increase in their position. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.

Progyny Stock Performance

Shares of PGNY stock opened at $20.36 on Friday. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $38.98. The stock has a fifty day moving average of $21.58 and a two-hundred day moving average of $18.66. The firm has a market capitalization of $1.74 billion, a PE ratio of 35.10, a price-to-earnings-growth ratio of 2.39 and a beta of 1.41.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.